Diaz Mora Prameyllawati on Going Beyond the Price Tag for Gene Therapies in Hemophilia
Diaz Mora Prameyllawati, PhD Candidate at Erasmus MC, shared on LinkedIn:
”Beyond the price tag of gene therapy
Gene therapies are often discussed in terms of their high price, which can range from €1 to €3.5 million per individual.
In our latest study on gene therapy for hemophilia, we went beyond the price tag and focused on what it actually takes to deliver these therapies in clinical practice.
To support successful and sustainable implementation, we developed:
- A detailed process map covering all care activities from site preparation to follow-up.
- Comprehensive cost catalogs capturing every component of care, enabling other hospitals and countries to estimate their own delivery costs.
These tools aim to inform economic evaluations, reimbursement discussions, and the real-world implementation of gene therapy for hemophilia.
More details in our latest publication.
This work was made possible through the support of the SYMPHONY consortium.
I sincerely thank all participating healthcare professionals for their openness and valuable insights during the interviews, as well as my supervisors and co-authors for their guidance and collaboration throughout the study.”
Read the full article here.
Article: Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice
Authors: Diaz M. Prameyllawati, Caroline M.A. Mussert, Martijn A.H. Oude Voshaar, Hester F. Lingsma, Marjon H. Cnossen, Michiel Coppens, Karina Meijer, Paul R. van der Valk, Frank W.G. Leebeek, Renske M.T. ten Ham

Stay updated on all scientific advances with Hemostasis Today.
-
May 30, 2026, 08:59Li-Chia Chen: Advancing Patient Care Through Pharmacist Innovation at KUTRRH
-
May 30, 2026, 08:58Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
-
May 30, 2026, 08:56Reidiel Suárez Borges: Understanding the INR in Anticoagulation Management
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center
-
May 29, 2026, 17:20Martin Widschwendter: How Molecular Detection Tests Could Transform Endometrial Cancer Care
-
May 29, 2026, 17:18Nina Lansbury: Supporting a Period Friendly World With Menstrual Health Research and Education
-
May 29, 2026, 17:16Ipsita Chatterjee: Red is Not Shame, Red is Power, Red is a Woman
-
May 29, 2026, 16:49Abdulrahman Nasiri: The Evolving Role of Romiplostim in SAA